Radiopharmaceutical and chemotherapy combinations in metastatic castrate-resistant prostate cancer: a new beginning?

摘要

Two manuscripts in this issue of Journal of Clinical Oncology are focused on patients with bone-metastatic castrate-resistant prostate cancer (CRPC) treated with a combination of docetaxel and samarium-ethylenediaminetetramethylenephosphonic acid (~(153)Srn-EDTMP). These data are significant from a variety of perspectives, not only because they involve novel combinations of therapy, but also because they potentially lay a foundation for new approaches to treat this common and too often fatal disease.